Keywords: MRSA treatment, Vancomycin, Pfizer, Zyvox, Cubist, Cubicin, Decision Resources, Sepsis, USA
Vancomycin continues to dominate MRSA treatment with up to 76% of US specialists using the drug; Study
Article | 25 May 2011
According to surveyed infectious disease specialists and internists in the USA, as well as hospital patient-level medical data, Decision Resources ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
